Cemiplimab was developed by which international pharmaceutical company and approved for use worldwide

Cemiplimab (Cemiplimab) is a fully human monoclonal antibody that is an immune checkpoint inhibitor and mainly targets programmed cell death receptor -1 (PD-1). By blocking the binding of PD-1 to its ligand, cimepilimab can restore the immune recognition and killing functions of T cells against tumor cells, thus exerting anti-tumor effects. The drug is mainly used clinically to treat locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer and other tumor types related to PD-1 indications.

Cimepilimab was developed by the USRegeneron pharmaceutical company. Regeneron is an internationally renowned biopharmaceutical company that focuses on the research and development of antibody drugs, gene therapy and immunotherapy. Its R&D team has extensive experience in the fields of monoclonal antibodies and immune checkpoint inhibitors. Cimepilimab is one of the representative immunotherapy drugs jointly developed by Regeneron and Sanofi, which reflects the collaborative research and development capabilities of the two companies in tumor immunotherapy.

Globally, cimepilimab has been approved for use by drug regulatory authorities in many countries and regions, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada. Approvals in various countries are mainly for locally advanced or metastatic cutaneous squamous cell carcinoma, and are gradually extended to indications such as non-small cell lung cancer. Approval for marketing means that the drug has been verified through rigorous clinical trials and shown to be safe and effective, making it an important choice for immuno-oncology treatment.

In terms of clinical application and drug purchase channels, cimepilimab is usually obtained through the oncology department of large tertiary hospitals or specialized cancer treatment centers, and patients need to use it under the prescription and guidance of a doctor. Globally, Regeneron and its partner companies ensure drug quality and traceability through rigorous pharmaceutical supply chains. For patients who need to purchase drugs across borders, they must obtain them through formal channels to ensure the safety, efficacy and legality of the drugs.

Keyword tags: cimepilimab, PD-1 inhibitor, cutaneous squamous cell carcinoma, immunotherapy, indications

Reference materials:https://pubmed.ncbi.nlm.nih.gov/?term=cemiplimab